Oncopeptides AB (publ)
SSE:ONCO.ST
7.264 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 31.648 | 35.22 | 8.355 | 118.295 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.663 | -1.079 | 0.006 | 53.121 | 14.403 | 4.54 | 0.345 | 0.271 | 0.024 | 0 | 0 |
| Gross Profit
| 28.985 | 36.299 | 8.349 | 65.174 | -14.403 | -4.54 | -0.345 | -0.271 | -0.024 | 0 | 0 |
| Gross Profit Ratio
| 0.916 | 1.031 | 0.999 | 0.551 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 121.186 | 106.948 | 217.657 | 679.926 | 866.214 | 548.273 | 322.051 | 197.771 | 89.725 | 43.845 | 28.071 |
| General & Administrative Expenses
| 60.843 | 68.878 | 84.093 | 175.459 | 197.662 | 72.046 | 55.298 | 34.688 | -17.492 | 9.504 | -5.879 |
| Selling & Marketing Expenses
| 136.439 | 119.601 | 58.102 | 698.346 | 456.529 | 127.409 | 51.126 | 15.16 | 0.63 | 0 | 0 |
| SG&A
| 197.282 | 188.479 | 142.195 | 873.805 | 654.191 | 199.455 | 106.424 | 49.848 | -17.492 | 9.504 | -5.879 |
| Other Expenses
| -5.985 | -5.681 | -2.153 | -67.64 | 70.874 | -8.336 | -9.175 | 0 | 131.974 | 0 | 38.989 |
| Operating Expenses
| 312.483 | 289.746 | 357.699 | 1,486.091 | 1,591.279 | 739.392 | 419.3 | 247.619 | 114.482 | 53.349 | 33.11 |
| Operating Income
| -283.498 | -253.447 | -349.35 | -1,420.917 | -1,591.279 | -739.392 | -419.3 | -247.62 | -114.482 | -53.35 | -33.11 |
| Operating Income Ratio
| -8.958 | -7.196 | -41.813 | -12.012 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.711 | 5 | 11.67 | -0.455 | -1.163 | -0.528 | -0.002 | 0 | 0.036 | 0.009 | 0.016 |
| Income Before Tax
| -284.209 | -248.447 | -337.68 | -1,421.372 | -1,592.442 | -739.92 | -419.302 | -247.62 | -114.446 | -53.341 | -33.094 |
| Income Before Tax Ratio
| -8.98 | -7.054 | -40.417 | -12.015 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.398 | 0.664 | 0.271 | 8.946 | 2.251 | 0.785 | 0.147 | -0.001 | 0.036 | 0.009 | 0.016 |
| Net Income
| -284.607 | -249.111 | -337.951 | -1,430.318 | -1,594.693 | -740.705 | -419.449 | -247.62 | -114.446 | -53.341 | -33.094 |
| Net Income Ratio
| -8.993 | -7.073 | -40.449 | -12.091 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.71 | -1.96 | -4.11 | -19 | -25.57 | -14.33 | -9.77 | -6.39 | -2.95 | -1.37 | -0.85 |
| EPS Diluted
| -1.71 | -1.96 | -4.11 | -19 | -25.57 | -14.33 | -9.77 | -6.39 | -2.95 | -1.37 | -0.85 |
| EBITDA
| -283.498 | -231.622 | -319.615 | -1,399.059 | -1,576.554 | -734.852 | -419.793 | -247.348 | -114.422 | -53.342 | -33.086 |
| EBITDA Ratio
| -8.958 | -6.576 | -38.254 | -11.827 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |